Witryna20 maj 2014 · Background: PICN is a novel, solvent- and protein-free, 100-110 nm particle formulation of paclitaxel stabilized with polymer and lipids using … WitrynaTearAct Technology consists of resin microparticle-complexed drug in a suspension form to improve the dosing frequency from TID to QD. The conversion of a solution product to a drug-resin complex suspension product prolongs the release of drug likely reducing the immediate exposure to drug and providing a slow, consistent, and sustained exposure.
Phase I study of weekly treatment with paclitaxel injection …
WitrynaSPARC’s proprietary Nanotecton TM technology is based on forming a complex of drug with polymer and lipids in an optimum ratio to achieve a ‘packing’ parameter that allows self-assembly of the composition into nanoparticles of 50-150 nm in … WitrynaNanotectonica examines the relationship between natural and architectural systems in the context of emerging technologies. It is a design research project, which studies … to dj set
Phase I study of docetaxel injection concentrate for nano …
WitrynaNiraj Bhatt's 5 research works with 41 citations and 886 reads, including: Paclitaxel injection concentrate for nanodispersion versus nab-paclitaxel in women with metastatic breast cancer: a ... WitrynaNANOTECTON is a trademark owned by SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED and filed on Tuesday, January 13, 2015 in the Computer & … Witryna7 sty 2024 · On Wednesday, October 3, 2012, a trademark application was filed for NANOTECTON with the United States Patent and Trademark Office. The USPTO has given the NANOTECTON trademark a serial number of 85744325. The federal status of this trademark filing is REGISTERED as of Tuesday, November 12, 2024. This … tod mit 24 ski